GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 4.800-5.000 for the period, compared to the consensus EPS estimate of 4.870. The company issued revenue guidance of -. GE HealthCare Technologies also updated its Q2 2026 guidance to EPS.
GE HealthCare Technologies Stock Down 2.3%
Shares of GEHC opened at $60.58 on Friday. The firm has a market cap of $27.56 billion, a P/E ratio of 14.49, a P/E/G ratio of 1.69 and a beta of 0.72. The stock has a 50 day simple moving average of $63.63 and a two-hundred day simple moving average of $71.23. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.22 and a quick ratio of 0.95. GE HealthCare Technologies has a 1 year low of $58.75 and a 1 year high of $89.77.
GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.07 by ($0.08). The business had revenue of $5.13 billion for the quarter, compared to analysts’ expectations of $5.04 billion. GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.The company’s revenue was up 7.4% compared to the same quarter last year. During the same period last year, the business posted $1.01 earnings per share. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. On average, analysts forecast that GE HealthCare Technologies will post 4.89 earnings per share for the current fiscal year.
GE HealthCare Technologies Dividend Announcement
Analysts Set New Price Targets
A number of research firms have issued reports on GEHC. HSBC decreased their price objective on shares of GE HealthCare Technologies from $100.00 to $90.00 in a research report on Thursday, April 30th. Argus reduced their price target on GE HealthCare Technologies from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. BMO Capital Markets began coverage on GE HealthCare Technologies in a research report on Wednesday, July 8th. They set a “market perform” rating and a $70.00 price target for the company. Stifel Nicolaus set a $80.00 price objective on GE HealthCare Technologies in a report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. cut their price objective on GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating on the stock in a research report on Thursday, April 30th. Ten equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, GE HealthCare Technologies has an average rating of “Hold” and an average target price of $76.41.
Check Out Our Latest Stock Report on GE HealthCare Technologies
Insiders Place Their Bets
In other news, CEO Peter J. Arduini acquired 4,169 shares of the business’s stock in a transaction on Thursday, April 30th. The shares were acquired at an average cost of $59.92 per share, with a total value of $249,806.48. Following the transaction, the chief executive officer owned 259,424 shares in the company, valued at $15,544,686.08. The trade was a 1.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO James Saccaro acquired 3,310 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was purchased at an average price of $60.60 per share, with a total value of $200,586.00. Following the acquisition, the chief financial officer owned 87,471 shares of the company’s stock, valued at $5,300,742.60. This represents a 3.93% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 21,847 shares of company stock valued at $1,361,355 over the last ninety days. 0.36% of the stock is owned by corporate insiders.
Key Headlines Impacting GE HealthCare Technologies
Here are the key news stories impacting GE HealthCare Technologies this week:
- Positive Sentiment: GE HealthCare reported preliminary second-quarter 2026 results and reaffirmed its full-year guidance, which suggests the business is still tracking in line with expectations and may be seeing momentum in key areas. GE HealthCare announces CFO transition; reports preliminary second quarter 2026 financial results and reaffirms guidance reflecting business momentum
- Positive Sentiment: The company’s revenue outlook appears steady, with Q2 revenue guidance roughly in line with Wall Street estimates, and management has indicated that second-half performance could improve as cost pressures ease. Can GE HealthCare Sustain Growth in Q2 Amid Persistent Cost Headwinds?
- Neutral Sentiment: GE HealthCare announced that CFO Jay Saccaro will step down, but the company framed the move as a transition rather than a crisis, which makes the near-term market impact uncertain. GE HealthCare CFO to step down
- Negative Sentiment: Ongoing securities-fraud investigations and shareholder-loss solicitations add legal uncertainty and can weigh on sentiment toward GEHC stock. GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
- Negative Sentiment: Another law firm expanded a securities-fraud probe tied to prior disclosures, reinforcing investor concerns about possible litigation risk. Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
- Negative Sentiment: GE HealthCare was downgraded by Zacks Research from “hold” to “strong sell,” which may add to selling pressure. Zacks Research downgrade
Institutional Trading of GE HealthCare Technologies
Several institutional investors have recently added to or reduced their stakes in the business. Compound Planning Inc. raised its position in GE HealthCare Technologies by 22.6% in the 4th quarter. Compound Planning Inc. now owns 3,299 shares of the company’s stock worth $271,000 after buying an additional 609 shares during the last quarter. Invesco Ltd. boosted its stake in shares of GE HealthCare Technologies by 1.6% in the 4th quarter. Invesco Ltd. now owns 7,003,172 shares of the company’s stock worth $574,400,000 after buying an additional 112,028 shares during the last quarter. Axxcess Wealth Management LLC increased its position in GE HealthCare Technologies by 34.4% during the fourth quarter. Axxcess Wealth Management LLC now owns 3,640 shares of the company’s stock valued at $299,000 after acquiring an additional 931 shares during the last quarter. Corient Private Wealth LLC lifted its holdings in GE HealthCare Technologies by 84.7% in the fourth quarter. Corient Private Wealth LLC now owns 101,191 shares of the company’s stock valued at $8,300,000 after acquiring an additional 46,394 shares during the period. Finally, Ameriflex Group Inc. grew its stake in shares of GE HealthCare Technologies by 146.0% during the 4th quarter. Ameriflex Group Inc. now owns 1,358 shares of the company’s stock valued at $111,000 after purchasing an additional 806 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.
GE HealthCare Technologies Company Profile
GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.
In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.
Featured Articles
- Five stocks we like better than GE HealthCare Technologies
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
Receive News & Ratings for GE HealthCare Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GE HealthCare Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
